FDA Approves Denosumab for Prevention of Skeletal-related Events in Multiple Myeloma

On Jan. 5, 2018, Amgen announced that U.S. Food and Drug Administration (FDA) has approved the company's supplemental Biologics License Application for Xgeva (denosumab) to expand the currently approved indication for the prevention of skeletal-related events in patients with bone metastases from solid tumors to include patients with multiple myeloma.

Read the corporate press release.

Posted 1/10/2018